Validation of the Bronchiectasis Severity Index in alpha-1 antitrypsin deficiency

Joshua De Soyza, Paul Ellis, Daniella Spittle, Anita Pye, Alice M Turner · 2026

Read Validation of the Bronchiectasis Severity Index in alpha-1 antitrypsin deficiency by Joshua De Soyza, Paul Ellis, Daniella Spittle, Anita Pye, Alice M Turner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0355956.txt.

Description

Joshua De Soyza leads a team of five checking whether a standard lung severity score works in a genetic lung disease, in PLOS ONE in 2026. Alpha-1 antitrypsin deficiency damages lungs and often brings bronchiectasis, chronically widened airways. A widely used severity index predicts death, hospitalization, and flare ups in ordinary bronchiectasis, but it had never been tested in this population. The team applied it to one hundred ninety-eight registry patients in Birmingham, nearly all with the severe genotype and most with COPD alongside.

The index sorted patients meaningfully. Survival differed significantly across its severity bands, exactly what a prognostic tool must do. The team also probed whether scores tracked lung function decline and quality of life measures. Validation in a rare disease subgroup matters because trials and clinics borrow tools from common diseases on faith. Here, at least for prognosis, the borrowed tool earned its place.

Catalog record

CREATORJoshua De Soyza, Paul Ellis, Daniella Spittle, Anita Pye, Alice M Turner
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24413
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0355956

Browse the full library · About the Tower of Babel